Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Single-dose, Three-way Crossover Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to 5 mg Mavacamten Intact Capsule in Healthy Participants
Conditions
Interventions
Treatment A: Mavacamten intact oral capsule
Treatment B: Mavacamten open capsule in suspension
+1 more
Locations
1
United States
Local Institution - 0001
San Antonio, Texas, United States
Start Date
January 10, 2024
Primary Completion Date
June 13, 2024
Completion Date
June 13, 2024
Last Updated
September 19, 2024
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions